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Sphingolipids (SLs) are structurally diverse lipids that are
defined by the presence of a long-chain base (LCB) backbone.
Typically, LCBs contain a single 4E double bond (DB) (mostly
d18:1), whereas the dienic LCB sphingadienine (d18:2) contains
a second DB at the 14Z position. The enzyme introducing the
14Z DB is unknown. We analyzed the LCB plasma profile in a
gender-, age-, and BMI-matched subgroup of the CoLaus cohort
(n  658). Sphingadienine levels showed a significant associa-
tion with gender, being on average 30% higher in females. A
genome-wide association study (GWAS) revealed variants in the
fatty acid desaturase 3 (FADS3) gene to be significantly associ-
ated with the plasma d18:2/d18:1 ratio (p  log 7.9). Meta-
bolic labeling assays, FADS3 overexpression and knockdown
approaches, and plasma LCB profiling in FADS3-deficient mice
confirmed that FADS3 is a bona fide LCB desaturase and
required for the introduction of the 14Z double bond. More-
over, we showed that FADS3 is required for the conversion of
the atypical cytotoxic 1-deoxysphinganine (1-deoxySA, m18:0)
to 1-deoxysphingosine (1-deoxySO, m18:1). HEK293 cells over-
expressing FADS3 were more resistant to m18:0 toxicity than
WT cells. In summary, using a combination of metabolic profil-
ing and GWAS, we identified FADS3 to be essential for forming
14Z DB containing LCBs, such as d18:2 and m18:1. Our results
unravel FADS3 as a 14Z LCB desaturase, thereby disclosing
the last missing enzyme of the SL de novo synthesis pathway.
Sphingolipids (SLs)2 are a diverse class of lipids that share a
long-chain base (LCB) backbone as a common structural ele-
ment. Forming an LCB is the first and rate-limiting reaction in
the de novo synthesis of SL (Fig. S1). During SL synthesis, LCBs
are usually N-acylated to a fatty acid (FA) of variable length
(C16–C26) forming ceramides and conjugated to variable head-
group structures forming complex SLs. LCBs are synthesized at
the endoplasmic reticulum by the enzyme serine palmitoyl-
transferase. The most abundant LCB in mammals is the 18-
carbon dihydroxy-amino-alkane sphingosine (d18:1) that is
formed by the conjugation of L-serine with palmitoyl-CoA. Ser-
ine palmitoyltransferase, however, can metabolize a variety of
other acyl-CoA in the range of C14–C18 and use alanine and
glycine as alternative substrates. This forms a broad variety of
LCBs, which differ by structure, function, and metabolism (1).
1-DeoxySLs are atypical SLs, which are generated from alanine
instead of serine and involved in a variety of pathological condi-
tions, including the rare hereditary sensory neuropathy type 1
(HSAN1) (2). Typically, LCBs present with a canonical 4E double
bond (DB). However, the -dienic sphingoid base sphingadienine
(d18:2) that is formed downstream of sphingosine (d18:1) has an
additional DB at the 14Z position (3, 4). Recently, we reported
that 1-deoxySO (m18:1) contains a 14Z DB but lacks the canon-
ical DB at the 4E position (5). Whereas the 4E DB is introduced
by the ceramide desaturase 1 (DEGS1), the enzyme responsible for
the introduction of the 14Z DB is not known. Here, we identified
fatty acid desaturase type 3 (FADS3) as a bona fide sphingoid base
desaturase introducing a DB in the 14Z position and therefore
responsible for converting d18:1 into d18:2 and 1-deoxySA
(m18:0) into 1-deoxySO (m18:1).
Results
Human plasma contains different SL classes, of which the
most abundant are sphingomyelins (SM), hexosylceramides
(HexCer), and ceramides (Cer). These classes are formed on a
variety of LCB backbone structures, and variations in their LCB
composition are associated with different pathological condi-
tions (6 –8). Differences in the LCB profile predict the risk for
future diabetes type 2 (T2DM) independent from classical risk
factors, such as BMI and blood glucose (9). Males and females
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have different risk profiles for T2DM. In men, T2DM is more
frequently diagnosed at lower age and BMI, whereas obesity is
more common in women. We therefore compared the LCB
profile in an age- and BMI-matched subgroup of female and
male participants of the CoLaus cohort (n  329 each). LDL
cholesterol, triglycerides, and fasting glucose were not different
between groups (Table 1), whereas total and HDL cholesterol
were higher and waist/hip ratio was lower in females (p  log
49.4). In plasma and tissue, the majority of LCBs is N-acylated
and conjugated to variable headgroups. Nonconjugated LCBs
in plasma are minor and less than 1% of the total. The combi-
nation of a variable LCB with a variable FA frequently results in
the formation of isomeric structures (e.g. d18:1/24:0 versus d18:
0/24:1), which interfere with the LCB analysis by LC-MS. To
avoid interference with the N-acyl chain, we subjected the
extracted lipids to a sequential acid/base hydrolysis (10) to
remove the conjugated FA and headgroups. We therefore
reported total LCB concentrations without considering previ-
ously conjugated N-acyl and headgroup structures.
The LCB profiling revealed d18:1 as the most abundant LCB
in plasma (57%) followed by d18:2 (21%), d16:1 (5%), and d17:1
(4.2%). The remaining LCB species were less than 5% in total
(Fig. 1A). Significant gender differences were seen for d18:2
(p  log 32.3) followed by d17:1 (p  log 15.5) and d16:1
(p  log 11.6) LCBs (Fig. 1B). In average, d18:2 was about 30%
higher in females, whereas its precursor d18:1 was only 10%
increased. This indicates that the d18:1 to d18:2 conversion
differs between genders. However, the enzyme responsible for
this conversion was not known.
To identify the responsible 14Z desaturase, we used
genome-wide SNP data, which were available for all European
individuals of the cohort (11). As the enzyme converts d18:1
into d18:2, we hypothesized that genetic variations in the
desaturase gene will be reflected by changes in the d18:1/d18:2
ratio. We therefore used this ratio as a metabolic outcome trait
for a GWAS on 1100 participants of the CoLaus cohort for
whom the LCB profile was already available from an earlier
study (9). The analysis revealed a group of adjacent SNPs, show-
ing a significant association with the d18:1/d18:2 ratio. The
strongest association was seen for SNP rs174455 (p  log
7.93), which is located in an intronic region of the fatty acid
desaturase 3 (FADS3) gene on chromosome 11q12.2–13.1 (Fig.
1D). The same region clusters two other desaturases, FADS1
and FADS2, which metabolize polyunsaturated fatty acids (12).
In contrast, the function of FADS3 was still elusive. The FADS3
gene spans 17.9 kb of genomic DNA and has the same structure
as FADS1 and FADS2, consisting of 12 exons and 11 introns.
On the protein level, FADS3 is 52 and 62% homologous to
FADS1 and FADS2, respectively.
To test whether FADS3 is a 14Z LCB desaturase, we
expressed the mouse and human FADS3 cDNA in HEK293
cells. Endogenous d18:2 levels in HEK293 cells were low, indi-
cating a low activity of the putative 14Z desaturase. For com-
parison, we also expressed the cDNA of mFADS1 and
mFADS2. Expression levels were comparable for all constructs
(Fig. 2A). Immune fluorescence microscopy showed an intra-
cellular colocalization of FADS3 with calnexin, indicating that
FADS3 is an ER protein (Fig. 2B).
Enzyme activity was tested in human and mouse FADS3-
expressing cells supplemented either with isotope-labeled
(d7)d18:0 or (d3)m18:0. The free LCBs were absorbed by the
cells (13) and metabolized to (d7)ceramide and downstream
products, such as (d7)SM and (d7)HexCer (Fig. S2A). After
48 h, the lipids were extracted and hydrolyzed, and the LCB
profile were analyzed by LC-MS. In both mFADS3- and
hFADS3-expressing cells, we observed a strong increase in
d18:2 (Fig. 2C and Fig. S2B), which was not seen in mFADS1- or
mFADS2-expressing cells. In addition, FADS3-expressing cells
showed an increased conversion of m18:0 into m18:1, indicat-
ing that the 14Z DB in 1-deoxySO is also formed by FADS3
(Fig. 2D and Fig. S2C). To test whether FADS3 acts on N-acy-
lated or free LCBs, we treated cells with fumonisin B1 (FB1).
FB1 inhibits ceramide synthase and therefore the N-acylation
of LCBs. In the presence of FB1, the conversion was about 70%
reduced, but a significant amount of (d7)d18:1 was still con-
verted into (d7)d18:2. This was confirmed in vitro, by adding
either the free LCB (d7)d18:1 or the N-acylated d18:1/6:0 to
cell-free extract of FADS3-expressing HEK cells. Both the free
and the N-acylated LCBs were effectively converted into their
dienic forms (Fig. 2F), indicating that FADS3 is capable of
metabolizing both free and N-acylated LCBs.
For further confirmation, we performed the reverse experi-
ments by knocking down endogenous FADS3 in HeLa cells,
which had a higher endogenous FADS3 expression than
HEK293 cells. Transfection with FADS3 siRNA (siFADS3)
abolished FADS3 expression almost completely compared with
cells transfected with control siRNA (siSCR) (Fig. 3A). LCB
profiling revealed that almost no isotope-labeled (d7)d18:2 was
formed in the absence of FADS3, whereas in siSCR-treated
cells, a significant conversion of (d7)d18:0 into (d7)d18:1 and
finally into (d7)d18:2 was observed (Fig. 3B). Similarly, the con-
version of isotope-labeled (d3)m18:0 into (d3)m18:1 was
mostly abolished in siFADS3-treated cells (Fig. 3C and Fig. S4).
Table 1
Baseline values of clinical parameters and long-chain base levels for
each group (significant differences in bold)
Parameters
Female Male -Fold
difference log(p)Mean S.D. Mean S.D.
n 329 329
Age 59.77 9.07 58.31 10.52 1.02 1.24
BMI 28.61 5.03 27.82 4.28 1.03 1.50
Waist/hip
ratio
0.86 0.07 0.94 0.06 0.91 49.39
Cholesterol
(total)
5.94 1.09 5.63 0.94 1.06 4.08
HDL 1.66 0.40 1.38 0.31 1.20 21.24
LDL 3.59 0.95 3.51 0.82 1.02 0.66
Trig 1.51 0.70 1.63 0.84 0.93 1.37
Glu 6.02 1.67 6.14 1.79 0.98 0.43
C16SO d16:1 19.63 5.73 16.58 5.21 1.18 11.58
C16SA d16:0 0.51 0.20 0.44 0.18 1.14 4.65
C17SO d17:1 9.52 2.63 7.91 2.28 1.20 15.45
C18PhytoSO t18:0 0.15 0.05 0.14 0.04 1.02 0.47
C18SO d18:1 97.23 19.15 88.32 16.54 1.10 9.45
C18SA d18:0 3.51 1.08 3.12 1.00 1.12 5.48
C18SAdienine d18:2 35.05 7.80 28.01 6.33 1.25 32.26
C19SO d19:1 2.45 0.96 2.16 0.91 1.14 4.12
C20SO d20:1 0.20 0.06 0.19 0.05 1.03 0.57
C20SA d20:0 0.02 0.01 0.02 0.01 1.02 0.28
1-DeoxySO m18:1 0.15 0.08 0.17 0.09 0.85 4.10
1-DeoxySA m18:0 0.08 0.04 0.09 0.04 0.95 0.85
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Finally, we analyzed the LCB profile in plasma of FADS3-
deficient mice (14). No d18:2 was detected in plasma of
FADS/ mice, whereas FADS/ mice had about 50% of the
WT levels (Fig. 3D).
To see whether the 14Z DB has biological relevance, we
cultured WT and FADS3-overexpressing cells with increasing
amounts of m18:0 and quantified the number of surviving cells
after 48 h. HEK293 cells overexpressing FADS3 were signifi-
cantly more resistant to m18:0 toxicity than WT cells (Fig. 3E).
As d18:2 plasma levels were higher in females, we compared
the FADS3 tissue expression between males and females using
the public gene expression data from the GTEx portal (https://
gtexportal.org).3 Overall, the highest FADS3 expression was seen
for peripheral nerve, aorta, and adipose tissue. The majority of
tissues showed higher FADS3 expression in females. The most
pronounced difference was seen for adipose tissues, with 194.6
transcripts per million (TPM) in females versus 166.7 TPM in males.
Discussion
Sphingadienine (d18:2) is an atypical sphingoid base that
contains two DBs, a 4E and a 14Z (3, 15). Whereas the 4E
3 Please note that the JBC is not responsible for the long-term archiving and
maintenance of this site or any other third party hosted site.
Figure 1. LCB profiling and genetic associations. A and B, long-chain base profile in human plasma. A, relative distribution of the most abundant LCBs in
human plasma. B, differences in the concentration of the major plasma LCBs between females (F) and males (M). C, relative distribution of the LCB species d18:0,
d18:1, and d18:2 in Cer, HexCer, and SM in human plasma. The LCBs reflect the sum of Cer (C16:0, C18:0, C20:0, C22:0, C24:0, and C24:1), SM (C16:0, C18:0, C20:0, C22:0, C24:0,
and C24:1), and HexCer (C16:0, C22:0, C24:0, and C24:1). D, Manhattan plot of the GWAS revealed SNP rs174455 on Chromosome 11 to be significantly associated
with the d18:1/d18:2 ratio (p  log 7.93). Error bars, S.D.
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DB is introduced by DEGS1 during SL de novo synthesis, the
enzyme introducing the 14Z DB was not known. However, in
a gender-, age-, and BMI-matched cohort, we identified d18:2
as the second most abundant LCB (Fig. 1A) and significantly
higher in females than in males. This confirms data from two
recent epidemiologic studies, which also report gender-specific
difference in d18:2-based SLs (16, 17).
Although, d18:2 was first described in the late 1960s (3), the
responsible enzyme forming the 14Z double was not known.
Based on genetic association studies in combination with in
vivo and in vitro experiments, we identified FADS3 as a bona
fide 14Z long-chain base desaturase. Data from the GTEx
database revealed generally higher FADS3 expression in
females for many tissues, including peripheral nerve and adi-
pose tissue, but also liver, kidney, and muscle. Higher FADS3
expression was also reported for female mice (18) and might
explain the gender-specific differences in d18:2 plasma levels.
Although human FADS3 was first cloned in 2000 (19), its func-
tion remained elusive. FADS3 is composed of an N-terminal cyto-
chrome b5-like domain and three histidine motifs at the C-termi-
nal ends, which is characteristic for membrane-bound front end
desaturases (20). In vitro studies indicated that FADS3 is specific
for trans-vaccenic acid (trans-11–18:1), catalyzing the synthesis of
a trans-11,cis-13-linoleic acid isomer (13 desaturation) (21).
Interestingly, an earlier GWAS on genetic determinants of circu-
lating sphingolipids found FADS3 to be strongly associated with
SM species containing monounsaturated N-acyl chains (22). As
d18:1-based SLs with unsaturated acyl chains (e.g. SM d18:1/24:1)
are isobaric to SLs with saturated fatty acids formed on a d18:2
backbone (e.g. SM d18:2/24:0), these associations could also refer
to -dienic SM species (Figs. S3 and S5).
FADS3 localizes to human chromosome 11q13 (23), which is
known as a cancer hotspot locus (19, 24). It is located in a gene
cluster together with FADS1 and FADS2, which were identified
previously as -5 and -6 desaturases. FADS3 mRNA expres-
sion responds inversely to FADS1 and FADS2 expression levels.
In FADS2-deficient mice, FADS3 expression increased 3-fold
(25), and reducing FADS1 and FADS2 expression by docosa-
hexaenoic acid and arachidonic acid increases expression of
FADS3 (26). FADS3 is spliced, yielding to alternative tran-
scripts, which are conserved in several mammalian and avian
species (18, 27). However, it is not yet clear whether these alter-
native transcripts are catalytically active.
Little is known about the function of d18:2-based SLs. Previ-
ously, plasma levels of d18:2 SLs were inversely associated with
the incidence of cardiovascular events (8), the body mass index,
and the HOMA (homeostatic model assessment) index (16). It
serves as a backbone for complex sphingolipids (Fig. 1C) and
forms -dienic LCB phosphates (SAdienine-1P) (29). Free
SAdienes and synthetic analogues exhibit cytotoxic and anti-
proliferative effects in cancer and noncancer cells (30, 31) and
were associated with the inhibition of colon tumorigenesis in
mouse models (32, 33). Mitochondrial and cellular pools of
d18:2-based ceramides were elevated in embryonic fibroblasts
derived from double-knockout BAX-BAK mice and a mouse-
derived immortalized iBMK cell line (34). It is noteworthy that
the 14 DB in d18:2 is in cis conformation, introducing a kink
into the otherwise straight LCB structure. This might affect the
lateral assembly of d18:2-based SLs in biological membranes and
could interfere with membrane nanodomain formation and
receptor clustering. In the first reports, FADS3 KO mice showed
no overt phenotype (14). No significant differences in survival, fer-
tility, or growth rate were seen. However, FADS3 KO mice were
not yet tested under challenged metabolic conditions, such as
high-fat diet. Genetic variants of FADS3 are associated with famil-
ial combined hyperlipidemia in the Mexican population (35), and
the FADS3 SNP rs174455 was negatively associated with docosa-
hexaenoic acid levels in red blood cell phospholipids (36).
1-DeoxySLs are an atypical class of toxic sphingolipids associ-
ated with the rare inherited neuropathy HSAN1 (37) and macular
telangiectasia type 2 (38). In contrast to canonical LCBs, m18:1
contains only a single DB in 14Z position but lacks the 4E DB
(5). Here we showed that FADS3 is also responsible for the con-
version of m18:0 into m18:1 (Figs. 2D and 3C and Figs. S2 and S4).
In addition, we showed that FADS3-expressing cells were more
resistant to m18:0 toxicity than WT cells (Fig. 3E). This supports
recent reports indicating that m18:0 based 1-deoxySL species are
more associated with toxic effects than their unsaturated forms
(39). In that respect, FADS3 might contribute to a physiological
detoxification of 1-deoxySLs.
It is not fully clear yet whether FADS3 activity is specific for
N-acylated LCBs or whether it can also metabolize the free
form. After blocking N-acylation with FB1, we still observed a
conversion of (d7)d18:1 into (d7)d18:2, albeit at reduced levels
(Fig. 2E). Also in vitro assays showed that FADS3 (Fig. 2F) is
capable in converting both the N-acylated and the free LCB.
However, as free LCBs are typically minor, the conversion of
free LCBs is likely of limited biological relevance.
We recently reported that DEGS1 deficiency causes leu-
kodystrophy and peripheral hypomyelination, which was asso-
ciated with a pathologically increased formation of saturated
dihydroSL species (13) and the formation of an atypical mono-
unsaturated d18:1 isomer. Further analysis showed that this
isomer contained a 14Z DB but lacked the canonical 4E DB.
This suggests that FADS3 can also metabolize saturated d18:0,
although the atypical d18:1 (14Z) isomer was only detected
under conditions with reduced DEGS1 activity.
In conclusion, we identified FADS3 as a 14Z LCB desaturase
introducing a 14Z DB into d18:1- and m18:0-based SLs and likely
also other LCB substrates. This illuminates the last obscure step in
Figure 2. FADS3 mediates the 14 LCB desaturation in mammalian cells. A, Western blotting of HEK293 cells stably expressing mFADS1–3 (Myc-DDK) and
hFADS1–3 (V5). B, intracellular localization of hFADS3-V5 (red) overlaps with the ER marker calnexin (green). Scale bar, 10 m. Insets, 3-fold magnification. Scale
bar, 5 m. C, cells stably expressing mFADS1–3 and hFADS3 cultured for 48 h with isotope-labeled (d7)d18:0. The levels of (d7)d18:2 were significantly elevated
in mFADS3- and hFADS3-overexpressing cells but not altered in mFADS1 and mFADS2 cells. D, FADS1–3– expressing HEK293 cells supplemented with
isotope-labeled (d3)m18:0 for 48 h. (d3)m18:1 levels were higher in FADS3-expressing cells compared with WT, mFADS1, and mFADS2 cells. E, HEK293 cells
supplemented with (d7)d18:1 in the presence or absence of FB1 (35 M). (d7)d18:2 formation was reduced but still detectable in the presence of FB1, indicating
that FADS3 can also metabolize the free LCB. F, FADS3 in vitro activity with the free LCB ((d7) d18:1) and the N-acylated form (d18:1/6:0). The free and the
N-acylated form were both rapidly converted into (d7)d18:2 and d18:2/6:0, respectively. Data are shown as mean  S.D. (error bars), n  3, paired t test; ***, p 
0.001; ****, p  0.0001; n.s., not significant.
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the SL de novo synthesis pathways, as the enzyme that forms d18:2
was not yet identified. The activity of FADS3 seems to be higher in
females and relates to gender-specific differences in the plasma
sphingolipidome. In addition, we propose that FADS3 could be
involved in the detoxification of 1-deoxySLs. However, further
studies are required to understand the role of FADS3 under phys-
iological and pathophysiological conditions.
Experimental procedures
Approvals
The Colaus study was conducted according to the princi-
ples expressed in the Declaration of Helsinki and approved
by the Institutional Ethics Committee of the University of
Lausanne.
Figure 3. FADS3 is required for 14Z LCB desaturation. A, HeLa cells transfected with siFADS3 or siSCR. The silencing of hFADS3 was confirmed by Western
blotting with a polyclonal antibody against FADS3. Calnexin was used as a loading control (n  3). B–D, sphingoid base profiling of cells and plasma. B, HeLa
cells were transfected with siSCR and siFADS3 for 72 h and subsequently cultured for 24 h in the presence of 2 M (d7)d18:0 and (d3)m18:0. The formation of
(d7)d18:2 was significantly decreased in the siFADS3-treated cells. No difference was seen for the precursors (d7)d18:0 and (d7)d18:1. C, the conversion of
(d3)m18:0 into (d3)m18:1 was also reduced in siFADS3-treated cells compared with controls (siSCR). Data are shown as mean  S.D. (error bars), unpaired t test;
*, p  0.05; ***, p  0.001. D, d18:2 was absent in plasma of the two FADS(/) mice (M1/M2), and about 50% in the FADS(/) mice compared with WT. Total
d18:1 levels were not different. E, WT and FADS3-overexpressing HEK293 cells were plated at low density (150,000 cells/well of a 24-well plate) and supple-
mented with increasing concentrations of m18:0 (0 –1.5 M). After 48 h, the number of attached cells was significantly higher in FADS3-overexpressing cells
than in WT. Data are shown as mean  S.D. (n  3) and compared by two-way analysis of variance with Bonferroni’s correction *, p  0.05; **, p  0.01; ***, p 
0.001; n.s., not significant. F, interplay between the two LCB desaturases DEGS1 and FADS3. DEGS1 introduces the 4E DB into d18:0, forming d18:1, whereas
FADS3 introduces the 14Z DB into d18:1 and m18:0.
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Animal studies were approved by the Cornell University
Institutional Animal Care and Use Committee (IACUC proto-
col 2011-0007).
Human samples and genome-wide association scan
Two subgroups of age- and BMI-matched females and males
(n  329 each) were selected from the CoLaus cohort (9, 40).
Genotyping and imputation of the cohort was described previ-
ously (41). Briefly, individuals with genotyping inconsistencies
or with genotyping efficiency below 90% were removed. SNPs
with genotyping efficiency below 70% or with Hardy–Weinberg
p values smaller than 1E7 were removed. Duplicate individu-
als and first and second degree relatives were identified by com-
puting genomic identity-by-descent coefficients, using PLINK
(42). Imputation was performed using the method of Marchini
et al. (43), using IMPUTE version 0.2.0, CEU haplotypes, and
the fine scale recombination map from HapMap release 21.
Given the non-Gaussian distribution of the examined LCBs,
inverse normal quantile transformation was applied, regressing
out age, sex, and the first four ancestry principal components.
The residual trait has been rescaled to have zero mean and unit
variance. Linear regression analysis has been performed for
2,557,249 imputed genetic markers as explanatory variables.
The probabilistic genotypes were converted to allele dosages.
Cells and cell culture
HEK293 and HeLa cells (American Type Culture Collection)
were cultured in Dulbecco’s modified Eagle’s medium (Thermo
Fisher Scientific) with 10% fetal bovine serum and 1% penicil-
lin/streptomycin (37 °C in 5% CO2). Transfection was done
using Lipofectamine 3000 (Thermo Fisher Scientific). Trans-
fected cells were cultured under Blasticidin (Thermo Fisher
Scientific) for selection. hFADS3 and control siRNA was
obtained from Origene and transfected with RNAiMAX
(Thermo Fisher Scientific) according to the manufacturer’s
protocol.
Immunohistochemistry
HeLa cells were transfected and grown for 24 h on 15-mm
coverslips, fixed in 4% paraformaldehyde (30 min, room tem-
perature), and washed in PBS. Cells were blocked for 2 h in PBS,
5% BSA, 1% normal goat serum, and 0.25% Triton X-100) and
incubated with the primary antibodies overnight, and anti-cal-
nexin antibody (Sigma, C4731) and anti-V5 antibody (Bio-Rad
MCA1360) were used. Secondary antibodies (1:2000, Invitro-
gen) and 4	,6-diamidino-2-phenylindole (Invitrogen) was
added for 4 h. Cells were mounted on glass slides with ProLong
Diamond Antifade Mountant (Thermo Fisher Scientific). Pic-
tures were acquired on a confocal laser-scanning microscope
(Leica SP8, Leica Microsystems, Wetzlar, Germany, HC PL
APO CS2 
63 numeric aperture, 1.4 oil) at 90.4 nm 
 90.4
nm 
 300 nm (x 
 y 
 z) resolution and analyzed using the Fiji
image-processing package (44).
Protein detection
Protein isolation and Western blotting were carried out as
described elsewhere (13).
Cloning
FADS1 (NM_013402.4), FADS2 (NM_004265.3), and FADS3
(XM_011545023.2) were amplified from a commercially available
cDNA library using the following primers: FADS1 Forward, cac-
catgggaacgcgcgctgcgagg; FADS1 Reverse, ttggtgaagataggcatctagc-
cag; FADS2 Forward, caccatggggaagggagggaaccag; FADS2
Reverse, tttgtgaaggtaggcgtccag; FADS3 Forward, caccatgggcg-
gcgtcggggagcc; FADS3 Reverse, ctgatggaggtaggcgtccagatg.
The PCR product was cloned into the pcDNA3.1 V5-His-
TOPO vector (Thermo Fisher Scientific) and verified using
Sanger sequencing. Myc-DDK–tagged mouse FADS1–3 plas-
mids were commercially available (Origene).
Lipidomics analysis
Lipidomics analysis was performed as described previously
(13, 28) using the internal standards (100 pmol/ml, Avanti Polar
Lipids): (d5) 1-desoxymethylsphinganine (m17:0), dihydrocer-
amide (d18:0:12:0), ceramide (d18:1/12:0), 1-deoxydihydrocer-
amide (m18:0/12:0), 1-deoxyceramide (m18:1/12:0), glucosyl-
ceramide (d18:1/8:0), and sphingomyelin (d18:1/12:0).
The plasma LCB profile was analyzed as described previously
(10). For quantification, (d5) 1-desoxymethylsphinganine (m17:0)
was used as an internal standard (Avanti Polar Lipids).
Metabolic labeling assay
250,000 Cells were seeded and cultured in 6-well plates to
70 – 80% confluence. New medium containing isotope-labeled
(d3)m18:0, (d7)d18:0, or (d7)d18:1 (Avanti Polar Lipids) was
added. After 24 or 48 h, cells were harvested, counted (Beckman
Coulter Vi-Cell XR), pelleted (600 
 g at 4 °C), and stored at
20 °C.
Activity assay
FADS3 cells were lysed by sonication, and the homogenate
was centrifuged at 13,000 
 g for 5 min. For each condition, 100
g of lysate in 100 l of PBS  1 mM NAD were incubated
with 500 pmol of (d7)d18:1 or d18:1/6:0 for 5 min. The products
were measured by LC-MS.
Statistical analysis
Statistical analysis was performed using GraphPad Prism 8. A
p value of 0.05 was considered statistically significant.
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